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Abstract
In multiple myeloma (MM) increased numbers of monoclonal plasma cells in the bone marrow 
induce localized osteolytic lesions that rarely heal, due to increased bone resorption and 
suppressed bone formation. Numerous studies reported the contributions that different cell types in 
the MM microenvironment make to MM growth and bone disease, but the role of matrix-
embedded osteocytes in MM, which comprise >95% of bone cells and are major regulators of 
osteoclast and osteoblast activity, is unclear. We report that osteocytes in MM-bearing bones 
physically interact with MM cells in vivo, undergo caspase3-dependent apoptosis, and express 
higher RANKL and Sclerostin levels than osteocytes from control mice. Mechanistic studies 
revealed that osteocyte apoptosis is initiated by activation of Notch signaling in osteocytes through 
direct contact with MM cells, and is further amplified by MM cell-secreted TNFα. This Notch/
TNFα induced osteocyte apoptosis increases osteocytic Rankl expression, the osteocytic 
Rankl/Opg ratio and the ability of osteocytes to attract osteoclast precursors to induce local bone 
resorption. Further, osteocytes in contact with MM cells express high levels of Sost/Sclerostin that 
decrease Wnt signaling in osteoblasts and inhibit osteoblast differentiation. Importantly, direct 
contact between osteocytes and MM cells reciprocally activates Notch signaling and increases 
Notch receptor expression in MM cells, in particular Notch3 and 4, and stimulates MM cell 
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growth. These studies reveal a previously unknown role for bidirectional Notch signaling between 
MM cells and osteocytes that enhances MM growth and bone disease, and suggest the potential of 
targeting osteocyte-MM cell interactions as a novel MM treatment.
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Introduction
Multiple myeloma (MM) is characterized by expansion of monoclonal plasma cells in the 
bone marrow (BM) that induce marked bone destruction in the majority of patients (1). MM 
patients present with severe bone pain caused by osteolytic lesions that rarely heal (2). The 
osteolytic lesions result from increased bone resorption and concomitant long-term 
suppression of bone formation. The bone/BM microenvironment is a major contributor to 
tumor growth and bone destruction in MM (3). The bone remodeling compartment is 
disrupted in MM allowing exchange of soluble factors and direct cell-to-cell contact 
between MM cells and bone cells (4). Previous studies demonstrated that multiple cytokines 
are secreted or induced by the interaction of MM cells with the different cell types in the 
bone microenvironment to increase bone destruction, including the receptor of activator 
nuclear factor-kappa B ligand (RANKL), the chemokine (C-C motif) ligand 3 (MIP1α) and 
interleukin-3 (IL-3). Further, MM-derived interleukin 7 (IL-7), dickkopf WNT signaling 
pathway inhibitor 1 (DKK1) and IL-3, as well as direct contact by MM cells with 
osteoblasts inhibit osteoblast differentiation (1, 5).
Although osteoclasts and osteoblasts remodel bone by resorbing or forming bone 
respectively, osteocytes, which constitute >95% of all bone cells, are the central regulators 
of these processes (6, 7). Osteocytes, although buried within bone mineral, extensively 
communicate with each other and with cells on the bone surface and in the marrow via 
cytoplasmic projections that run along canaliculi and form the osteocyte network. This 
network allows cell-to-cell communication and distributes osteocyte-secreted molecules that 
regulate osteoblast and osteoclast function. Osteocytes are the primary producers of 
Sclerostin, the product of the Sost gene, a potent inhibitor of bone formation, and are a major 
source of RANKL, the central osteoclastogenic factor (8, 9). Lack of Sclerostin increases 
osteoblast number and activity, and deletion of osteocytic RANKL inhibits osteoclast 
formation and bone resorption, demonstrating that osteocytes are key regulators of 
osteoblast and osteoclast activity (10–12). Moreover, apoptotic osteocytes, which 
accumulate with skeletal disuse, glucocorticoid excess or estrogen deficiency, increase local 
bone resorption by attracting osteoclast precursors to particular areas of bone (6, 13). 
Although knowledge of the role of osteocytes and the osteocytic network in bone 
homeostasis and common skeletal diseases has greatly increased, the contribution of 
osteocytes to the development and progression of cancer involving bone is just beginning to 
be defined.
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In the current study, we determined if reciprocal communication between MM cells and 
osteocytes occurs and explored the mechanisms involved and the consequences of these 
interactions for the progression of MM bone disease.
Materials and Methods
Reagents
Reagents used in this study can be found in Supplementary Methods.
Cells and culture conditions
L. Bonewald (University of Missouri at Kansas City, USA) provided the murine MLO-A5 in 
1997 and MLO-Y4 in 2001 osteocyte-like cells (14, 15). JJN3, 5TGM1 and MM1.S MM 
cell lines were provided by N. Giuliani (University of Parma, Italy) in 2006, B. Oyajobi 
(University of Texas at San Antonio, USA) in 2007, and S. Rosen (Northwestern University, 
USA) in 2003 (16–18). R. Jilka (University of Arkansas for Medical Sciences, USA) 
provided the OB-6 osteoblast-like cells in 1997 (19). Non-adherent osteoclast precursors 
were collected as described before (20). After informed consent, CD138+ cells from MM 
patients were prepared as previously detailed (16). Studies were approved by the Indiana 
University School of Medicine Institutional Review Board. Cell lines were authenticated by 
morphology, gene expression profile, and tumorigenic capacity (MM cells). Co-cultures 
were established by 1) adding MM cells on top of osteocyte-like cells, 2) adding MM cells 
in transwell chambers in a 1:5 ratio (osteocytic:MM), or 3) adding 50% conditioned media 
(CM) from 48h-culture of MM cells to osteocytes. DEVD (50nM), anti-TNFα (0.3μg/mL) 
or GSIXX (2.5–10μM) were added 1h before addition of MM cells or CM. MLO-A5 cells 
were treated with 0.01ng/mL TNFα, 5ng/mL TGFβ or 10ng/mL interleukin 6 (IL-6) for 4–
24h. For Notch activation, MLO-A5 cells were cultured on DLL1-IgG2 or control IgG2-
coated plates for 24h. For OB-6 osteoblast-like cell differentiation, cells were cultured with 
osteogenic media (OM; 0.2 mM ascorbic acid, 10 mM β-glycerophosphate) or OM 
containing 50% of CM from MLO-A5 or JJN3 cells cultured alone, or from JJN3 directly 
co-cultured with MLO-A5 cells.
Ex vivo bone organ cultures
This assays were performed as previously described (21). Detailed description of the assay 
can be found in Supplementary Methods.
Cell viability and apoptosis
MM cells were separated from adherent osteocyte-like cells using EDTA. Cell death was 
quantified by trypan blue uptake and apoptosis by chromatin condensation and nuclear 
fragmentation of cells transfected with nuclear green fluorescent protein (nGFP) (22, 23). At 
least 100 cells in 5 different fields selected by systematic random sampling were examined 
for each experimental condition. Representative photomicrographs were taken with an 
EVOS FLCell Imaging System (Life technologies, Grand Island, NY, USA).
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Cell proliferation analysis
Viable cells were enumerated by trypan blue exclusion. Fluorescence emitted by 5TGM1-
GFP cells was measured in a SpectraMaxi3 microplate reader (Molecular Devices, 
Sunnyvale, CA, USA), set at 485 nm/520 nm. 5TGM1-GFP cell numbers linearly correlated 
with fluorescent units (RFU) (Suppl. Figure 1A).
Transfections
MLO-A5 cells were transiently transfected using Lipofectamine-Plus (Invitrogen) (23, 24).
Gene expression analysis
mRNA expression was quantified as previously described (25). Murine soluble RANKL, 
OPG or human TNFα were quantified by Enzyme-linked immunosorbent assays (ELISA, 
R&D systems) of culture supernatants.
Western blot analysis
The assays were performed as described previously (25). Detailed descriptions of antibodies 
can be found in Supplementary Methods.
Osteoclast precursor migration
48h-CM from JJN3, MLO-A5, or from JJN3 and MLO-A5 co-cultured in direct contact was 
placed in the bottom of 8 μm pore chambers to attract murine non-adherent BM cells (26). 
Detailed description of the assay can be found in Supplementary Methods.
Mouse model of human MM
6wk-old female SCID mice B6.CB17-Prkdcscid/SzJ (Jackson laboratories, Bar Harbor, 
Maine, USA) and NIH-LystbgFoxn1nuBtkxid (Charles River Wilmington, Massachusetts, 
USA) were injected intratibially with JJN3 cells or saline and sacrificed 4wks later (16). 
Detailed information regarding imaging and micro-CT analysis can be found in 
Supplementary Methods. Studies were approved by the Institutional Animal Care and Use 
Committee of the Indiana University School of Medicine. The sample size was calculated 
based on a previous study (16).
Immunohistochemistry
Antigen detection was performed on paraffin-embedded tibiae as described before (25). 
Detailed descriptions of antibodies can be found in Supplementary Methods.
Acid etching scanning electron microscopy (SEM)
The assays were performed as described previously (27). Detailed description of the assay 
can be found in Supplementary Methods.
Statistical analysis
Data were analyzed using SigmaStat (SPSS Science, Chicago, IL). Differences between 
means were evaluated using unpaired T-test, one-way, or two-way ANOVA, followed by 
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pair-wise multiple comparisons using Student-Newman-Keuls method. Means ± standard 
deviation (SD) are reported. P values <0.05 were considered significant.
Results
MM cells increase osteocyte apoptosis and osteocytic RANKL and Sclerostin production 
in an in vivo model of MM bone disease
Our murine model of human MM is well-established and reproduces all features of human 
MM-induced bone disease (16). Osteolytic lesions were first detected radiographically 2wks 
after JJN3 cell injection (Suppl. Figure 1B) and their size progressively increased up to 4wks 
(Figure 1A). Micro-CT analysis of JJN3-involved tibia performed at 4wks confirmed the 
presence of osteolytic lesions and demonstrated decreased trabecular bone volume (BV/TV), 
trabecular number (Tb.N.), trabecular thickness (Tb.Th.) and increased trabecular separation 
(Tb.Sp.) compared to controls (Figure 1B). The percentage of apoptotic osteocytes, stained 
with an anti-active CASP3 antibody, was increased 2 fold in bones injected with JJN3 cells 
compared to controls (Figure 1C). Moreover, the percentage of osteocytes expressing 
RANKL and Sclerostin was significantly higher in JJN3-injected mice compared to controls. 
These findings suggest that in addition to survival, osteocyte gene expression is altered in 
MM-bearing bones. Histological analysis of MM bearing bones showed that MM cells were 
adjacent to the bone surface, and acid etching-SEM images revealed that osteocytic dendritic 
processes were in direct contact with MM cells in the marrow (Figures 1D and E). Thus 
osteocytes are in close contact with MM cells, suggesting that MM-induced changes in 
osteocytes may result from cell-to-cell contact and/or exchange of soluble factors between 
osteocytes and MM cells.
Osteocyte apoptosis is initiated by MM cell-mediated activation of Notch signaling in 
osteocytes and amplified by MM cell-derived TNFα
In vitro co-cultures between osteocyte-like MLO-A5 cells and MM cells were performed to 
determine the mechanisms responsible for the increased osteocyte apoptosis and up-
regulation of RANKL and Sclerostin observed in osteocytes in MM-bearing bones. 
Communication between MM cells and bone cells, including osteocytes, can occur in 
different manners: 1) via secretion of soluble factors, 2) via direct cell-to-cell contact or 3) a 
combination of both. First, direct cell-to-cell cultures were established to determine the 
effect of physical interactions with MM cells on osteocyte apoptosis. Co-culture of MLO-A5 
cells in direct contact with human JJN3 MM cells induced a 2–3 fold increase in MLO-A5 
cell death (1–4% vs 6–15% in MLO-A5 alone vs. MLO-A5 cells co-cultured with JJN3 
cells) (Figure 2A). Cell death was detected at 8h and progressively increased at 24 and 48h. 
To elucidate the effect of factors released by MM cells on osteocyte apoptosis, the cell types 
were separated by a porous membrane that prevents physical interactions and only allows 
exchange of soluble factors. Co-culture of JJN3 and MLO-A5 cells separated by transwell 
chambers did not increase cell death at 8 or 24h, but it did at 48h (1–3% vs 8–13%) (Figure 
2B). These results suggest that different mechanisms mediate the early and late increases in 
osteocyte cell death induced by MM cells. Co-culture of MLO-A5 cells with JJN3 cells or 
JJN3-CM increased the percentage of MLO-A5 cells exhibiting chromatin condensation and 
nuclear fragmentation, sine qua non features of apoptosis (Figure 2A and B). Moreover, 
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osteocyte death was inhibited by the CASP3 inhibitor, DEVD, at all time-points confirming 
that it was due to apoptosis (Figure 2A, 2B, and Suppl. Figure 1C). Co-culture of MLO-A5 
cells with CD138+ cells from 6 different MM patients (Figure 2A) or conditioned media 
(CM) from CD138+ cells from a MM patient (Figure 2B) also increased MLO-A5 cell 
apoptosis. Similar results were obtained when MLO-A5 were co-cultured with human MM.
1s or murine 5TGM1 MM cells, or when MLO-Y4 cells, another murine osteocytic cell line, 
were co-cultured with JJN3 cells (Suppl. Figure 1D).
Notch signaling is activated by cell-to-cell contact and regulates cell proliferation and 
apoptosis in multiple cell types (28). Further, Notch signaling is aberrantly activated in MM 
cells due to the over-expression of Notch receptors and ligands (29, 30), demonstrating that 
MM cells are potential signalers as well as targets of Notch. We therefore assessed if direct 
interactions between MM cells and osteocytes activate Notch in these cells and the potential 
biological consequences. Direct contact of MLO-A5 cells with JJN3 MM cells activated 
Notch signaling in MLO-A5 cells, as shown by the increased expression of the Notch target 
gene hairy/enhancer-of-split related with YRPW motif 1 (Hey1) (Figure 2C) and hairy and 
enhancer of split 1 (Hes1), which persisted up to 48h (Suppl. Figure 1E). JJN3 cell 
activation of osteocytic Notch signaling was suppressed by the Notch inhibitor GSIXX, 
confirming the specificity of the effect (Figure 2C). Hey1 expression was also increased in 
MLO-A5 cells co-cultured with CD138+ cells from 3 of 5 MM patients (Figure 2C). As 
expected, Notch activation (Hey1 and Hes1) in osteocytes did not occur when MLO-A5 
cells were co-cultured with MM cells in transwell chambers (Suppl. Figure 1F). MM1.s or 
5TGM1 MM cells also increased the Notch target gene expression in osteocyte-like MLO-
A5 or MLO-Y4 cells (Suppl. Figure 1F). In addition, interactions with JJN3 cells rapidly 
upregulated the expression of receptors Notch3 and Notch4 in MLO-A5 cells, whereas 
Notch1 or Notch2 receptor expression was unchanged (Figure 2D). Moreover, the levels of 
NOTCH3 and of NICD3, the active form and downstream effector of the receptor Notch3, 
were elevated in tumor-bearing bones compared to control bones, demonstrating that Notch 
signaling activation also occurs in vivo (Figure 2E and F).
To evaluate the potential impact of gain-of-function of Notch signaling on osteocyte life 
span, MLO-A5 cells were transfected with nGFP and the Notch intracellular domains 
(NICD) 1 or 2, which translocate to the nucleus and activate Notch target gene transcription. 
Cells expressing either NICD1 or NICD2 exhibited increased apoptosis compared to vector 
controls (Figure 3A). Moreover, MLO-A5 cells cultured on plates coated with the Notch 
ligand DLL1 expressed higher levels of Hes1, confirming Notch activation, and had 
increased cell death (2- to 5-fold) compared to control cells cultured on IgG2 (1–2% vs 5–
9% in control vs DLL1 treated cells). DLL1-induced death was completely inhibited by the 
Notch inhibitor GSIXX or by DEVD (Figure 3B), indicating that Notch activation is 
sufficient to trigger osteocyte apoptosis. Consistent with this observation, GSIXX 
completely blocked osteocytic cell death induced by direct co-culture with JJN3 cells or 
CD138+ cells from a MM patient at 8h or 24h (Figure 3C). In contrast, GSIXX only 
partially prevented MLO-A5 cell death measured at 48h, suggesting that factors secreted by 
MM cells accumulated during culture contribute to osteocyte apoptosis at later time points. 
In support of this notion, levels of TNFα, a recognized inducer of osteoblast and osteocyte 
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apoptosis (31), increased 4-fold from 4 to 48h in CM from JJN3 cell cultures (Figure 3D), 
and addition of TNFα increased MLO-A5 cell death (Suppl. Figure 1G). Consistent with a 
role for MM-secreted TNFα in MM-induced osteocyte apoptosis, the decrease in osteocyte 
viability induced by JJN3-CM was blocked by DEVD or by a neutralizing anti-human 
TNFα antibody, but not by GSIXX (Figure 3D). Moreover, GSIXX or anti-TNFα only 
partially inhibited cell death, whereas the combination of both completely blocked the 
increase in osteocytic cell death induced by direct co-culture of MLO-A5 cells with JJN3 
cells for 48h (Figure 3E). These findings suggest that MM cells induce osteocyte apoptosis 
by activating Notch and TNFα signaling pathways in osteocytes.
Osteocyte apoptosis increases the osteoclastogenic potential of osteocytes and 
stimulates osteoclast precursor recruitment
We then investigated the consequences of osteocyte apoptosis on the osteoclastogenic 
potential of osteocytes. MLO-A5 cells co-cultured with JJN3 MM cells exhibited increased 
Rankl expression at the mRNA and protein levels (Figure 4A). Further, CD138+ cells from 3 
of 4 MM patients also increased Rankl transcripts in MLO-A5 cells. Like apoptosis, Rankl 
expression in osteocytes was increased by either direct or indirect contact with MM cells, 
suggesting that soluble factors secreted by MM cells were responsible. Similar results were 
obtained with other MM and osteocyte-like cell lines (Suppl. Figure 2A). Among several 
cytokines secreted by MM cells known to upregulate Rankl (32), only TNFα increased 
Rankl mRNA in MLO-A5 cells after 4h (Suppl. Figure 2B) or 24h. Moreover, anti-TNFα 
significantly blunted the increased Rankl mRNA levels in MLO-A5 cells treated with CM 
from JJN3 cells (Figure 4B). Inhibition of osteocyte apoptosis by DEVD similarly reduced 
Rankl levels to those observed with anti-TNFα.
We next determined the effect of osteocyte apoptosis on osteoclast precursor recruitment. 
CM from MLO-A5 cells cultured alone significantly increased osteoclast precursor 
migration compared to control media, whereas CM from JJN3 cells did not (Figure 4C). CM 
from JJN3 and MLO-A5 cells co-cultured in direct contact enhanced osteoclast precursor 
chemotaxis by 50% compared to CM from MLO-A5 cultured alone. This effect was 
inhibited by blocking osteocyte apoptosis with DEVD or by the combination of GSIXX and 
anti-TNFα. Taken together, these results suggest that MM-induced osteocyte apoptosis, 
even when modest, is sufficient to increase osteocytic Rankl expression and potentiate 
osteocyte-mediated recruitment of osteoclast precursors.
MM cells upregulate Sost expression in osteocytes, decrease Wnt signaling and inhibit 
osteoblast differentiation
Consistent with the increased Sclerostin expression in osteocytes in the in vivo MM mouse 
model, direct co-culture with JJN3 MM cells up-regulated Sost mRNA expression in MLO-
A5 cells by 3-fold as early as 4h (Figure 5A), which remained elevated up to 24h (Suppl. 
Figure 2C). Simultaneously with Sost upregulation, the expression of osteoprotegerin (Opg), 
a Wnt target gene, was decreased by 50%, both at mRNA (Figure 5A) and protein level 
(Suppl. Figure 2D). Similarly, the mRNA levels of the other Wnt target genes Axin2 and 
Smad family member 6 (Smad6) (25, 33, 34) were also decreased. In contrast, Sost/Wnt 
target gene expression was not altered when MM and MLO-A5 cells were not in direct cell-
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to-cell contact. Sost upregulation induced by MM cells was also recapitulated in a three 
dimensional ex vivo bone organ model containing authentic osteocytes (Figure 5B). These 
findings suggest that interactions between osteocytes and MM cells upregulate the 
expression of Sost in osteocytes, which in turn decreases Wnt signaling.
We next examined the consequences of MM-induced upregulation of osteocytic Sost/
Sclerostin on osteoblast differentiation. Wnt/β catenin signaling is critical for osteoblast 
differentiation and this pathway is tightly regulated by pre-receptor antagonists, including 
the potent osteoblast inhibitor Sclerostin secreted by osteocytes (35). CM from MLO-A5 
cells co-cultured with JJN3 MM cells in direct contact markedly decreased the expression of 
the osteoblast markers alkaline phosphatase (Alp), collagen 1a (Col1a), runt related 
transcription factor 2 (Runx2) and bone gamma carboxyglutamate protein (Bglap) in OB-6 
osteoblastic cells cultured under osteogenic conditions (Figure 5C). Expression of the Wnt 
target genes Axin2 and Smad6 was also significantly decreased by CM from MLO-A5-JJN3 
co-cultures. The expression of these genes was unchanged by treatment with CM from 
MLO-A5 or JJN3 cells cultured separately.
Taken together, these results demonstrate that direct interactions between osteocytes and 
MM cells increase expression of Sost/Sclerostin in osteocytes, decrease Wnt signaling/β 
catenin and inhibit osteoblast differentiation.
Osteocytes activate Notch signaling to increase MM cell proliferation, and alter the Notch 
receptor repertoire in MM cells
Because Notch signaling can be bidirectional, we next examined if osteocytes modulate 
Notch signaling in MM cells. Co-culture of 5TGM1 cells in direct contact with MLO-A5 
cells for 4h increased Hes1 and Hey1 expression by 2–4 fold in MM cells compared to MM 
cells cultured alone (Figure 6A). Similar upregulation in Hes1 expression was found in 
CD138+ cells from 3 of 4 MM patients examined (Figure 6A and E) and in 5TGM1 cells co-
cultured in direct contact with MLO-Y4 cells (Suppl. Figure 3A). GSIXX blocked the 
osteocyte-induced upregulation of Hes1 and Hey1 in 5TGM1 cells (Figure 6B). These 
results indicate that osteocytes activate Notch signaling in MM cells.
Co-culture of 5TGM1 cells in direct contact with MLO-A5 cells markedly increased the 
proliferation of 5TGM1 cells in a time-dependent manner (Figure 6C), whereas no changes 
were observed when cells were co-cultured without direct contact (Suppl. Figure 3B). 
Further, inhibition of Notch signaling with GSIXX prevented in a dose-dependent manner 
the increased proliferation of 5TGM1 cells and CD138+ cell from a MM patient induced by 
MLO-A5 cells (Figure 6C and E). Higher doses of GSIXX also inhibited proliferation of 
5TGM1 cells cultured alone at 48h, and all doses were inhibitory at 72h of culture (Figure 
6C).
Osteocyte-like MLO-A5 cells did not activate Notch signaling in all MM cells tested. Thus, 
MLO-A5 cells did not increase Notch target gene expression or stimulate MM cell 
proliferation in 1 of 4 CD138+ cell preparations from MM patients (Figure 6F), or in MM1.s 
or JJN3 MM (Suppl. Figure 3C). We next examined whether differences in proliferative 
responses of MM cells to osteocytes were due to differences in their Notch receptor 
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repertoire. 5TGM1 cells, which readily respond to osteocytic cell interactions by activating 
Notch, express higher Notch3 levels (20-fold), and lower Notch1 and 2 compared to JJN3 
cells in which osteocytic interactions do not activate Notch (Suppl. Figure 3D). None of the 
MM cell lines expressed detectable levels of Notch4 when cultured alone. These results 
show that different MM cells express different levels of Notch receptors, and suggest that 
osteocytes may activate Notch signaling in MM cells through Notch3, leading to increased 
MM cell proliferation. Moreover, osteocytic interactions rapidly upregulated Notch3 
expression in 5TGM1 cells and induced the expression of Notch4, which is undetectable in 
MM cells cultured alone (Figure 6D). Further, culture of 5TGM1 MM cells with authentic 
osteocytes in ex vivo bone organ cultures activated Notch signaling and increased the 
expression of Notch3 and 4 without altering Notch1 or 2 mRNA levels (Figure 6G). 
Similarly, CD138+ cells from a MM patient that exhibit Notch activation induced by 
osteocytes also displayed upregulation of Notch3 (Figure 6E), whereas no changes were 
found in other Notch receptors. In contrast, no changes in the expression of Notch3 were 
observed in CD138+ cells from a MM patient that did not show activation of Notch 
signaling after contact with MLO-A5 cells (Figure 6F). MLO-A5 cells also upregulated 
Notch1 and 2 in 5TGM1 cells at later time points (Figure 6D). These results demonstrate 
that osteocytes change the Notch receptor repertoire expressed by MM cells. Thus, the 
capacity of osteocytes to alter the Notch receptor repertoire on MM cells may regulate 
osteocyte enhancement of MM cell growth.
Discussion
Osteocytes play a central role in bone homeostasis by regulating osteoclast and osteoblast 
activity, and premature death of osteocytes leads to targeted bone resorption during skeletal 
disuse and estrogen loss (6). We report that osteocytes also contribute to a 
microenvironment favorable for the progression of MM and its associated bone disease. 
First, we show that osteocytes physically interact with MM tumors in vivo which increases 
Sclerostin and RANKL production by osteocytes, and reduces osteocyte viability. Second, 
the reduced viability of osteocytes is due to apoptosis triggered by MM cell-mediated 
activation of Notch signaling and sustained by MM-derived TNFα. Third, elevated 
osteocyte apoptosis increases osteocytic Rankl expression and enhances the ability of 
osteocytes to attract osteoclast precursors. Fourth, the increase in Sost/Sclerostin decreases 
Wnt signaling and inhibits osteoblast differentiation. Fifth, osteocytes induce reciprocal 
activation of Notch signaling in MM cells, which in turn enhances MM cell proliferation, 
and alters the Notch receptor repertoire on MM cells. Importantly, these results were 
validated in in vivo and in vitro, as well as in a novel ex vivo model, using several MM cell 
lines and CD138+ cells from MM patients. Taken together, these findings demonstrate that 
interactions between MM cells and osteocytes within the bone/BM microenvironment 
generate a permissive niche for MM cell growth and bone destruction (Figure 7). Thus, 
targeting osteocytes and their derived factors might represent a novel approach to treat MM 
bone disease.
Consistent with our findings showing that osteocytes induce MM cell growth by activating 
Notch signaling, several studies have shown that dysregulation of Notch signaling increases 
MM growth (36–38), and paracrine Notch activation mediated by BM stromal cells 
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increases MM cell proliferation, through NOTCH1 and 2 signaling (30, 39, 40). However, 
Notch3 and 4 appear to mediate the osteocytic effects, suggesting that regulation of Notch 
activation in MM is mediated by complex paracrine interactions with different cell types 
within the bone/BM microenvironment. Further, the changes in the Notch receptor repertoire 
on MM cells induced by osteocytic interactions could impact both the homotypic and 
heterotypic cell-to-cell interactions of MM cells. Although the specific roles of Notch3 and 4 
in MM are not fully understood, selective Notch receptor targeting may allow control of 
MM cell growth and its associated bone disease. Future studies to investigate this possibility 
and to identify relevant Notch ligands on osteocytes are warranted.
The increased prevalence of osteocyte apoptosis observed in our in vivo model is consistent 
with a previous report in bone biopsies from MM patients (17), although the mechanism of 
this phenomenon was not addressed. We show here that osteocyte apoptosis induced by MM 
cells is triggered by activation of Notch signaling followed by induction of the caspase 
cascade, and maintained by MM-cell derived TNFα. However, Giuliani et al were unable to 
block osteocyte apoptosis by neutralizing TNFα (17). This discrepancy, together with their 
inability to detect changes in osteocytic RANKL, could be explained by the use of cells lines 
at different stages of differentiation of the osteoblastic lineage. We used the late osteoblast/
early osteocyte-like MLO-A5 cell line that expresses the recognized osteocytic genes Sost/
Sclerostin and Rankl, whereas the HOB-01 pre-osteocytic cells used in the Giuliani study do 
not. Moreover, we validated our in vivo observations and mechanistic studies using MLO-
Y4 cells, an additional osteocytic cell line widely used as an osteocyte model, and confirmed 
our findings in authentic osteocytes using ex vivo bone organ cultures. Our results 
demonstrate that murine and human MM cell lines and CD138+ from MM patients act as 
Notch signalers in osteocytes that concurrently with MM-secreted TNFα induce osteocyte 
apoptosis.
Although our current findings demonstrating different outcomes of Notch activation in MM 
cells (proliferation) versus in osteocytes (apoptosis) may appear counterintuitive, they are 
consistent with earlier studies showing the cell type- and context-dependent nature of Notch 
signaling. Thus, whereas activation of Notch signaling protects several cancer cell types 
from apoptosis (36, 41), it induces apoptosis of neural progenitor cells (42), CD34+ 
hematopoietic stem/progenitor cells (43), and osteocytes (this report). Similarly, activation 
of canonical Wnt signaling inhibits apoptosis in different cells of the osteoblastic lineage 
(31, 44), whereas it increases apoptosis in hematopoietic stem/progenitor cells (45) or in 
melanoma cells (46). These findings show that the same signaling pathway can elicit 
different biological responses depending on the ligands/signals present in a particular 
microenvironment, the receptor repertoire exhibited by the target cell, and the intracellular 
machinery that integrates extracellular cues and transduces them into biological outcomes.
Osteocyte-derived interleukin 11 has been shown to contribute to osteoclast differentiation 
in MM (17). We show that apoptotic osteocytes attract osteoclast precursors more potently 
than MM cells in our in vitro system. Further, although relatively modest, the increased 
osteocyte apoptosis was sufficient to upregulate osteocyte Rankl. These findings suggest that 
similar to other pathological conditions, MM-induced osteocyte apoptosis plays a central 
role in osteoclast recruitment and may initiate and/or sustain bone resorption within the focal 
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lesions observed in MM patients. Further studies are warranted to determine whether 
osteocyte apoptosis leads to osteoclast differentiation in MM and to identify the molecular 
mediators.
Sclerostin levels are elevated in the sera of MM patients and correlate with reduced 
osteoblast function and poor patient survival (47). However, the source of Sclerostin 
remains unclear. CD138+ cells from MM patients were reported to express Sclerostin (48); 
but we could not detect Sost mRNA in any patient CD138+ cells studied. In contrast, our in 
vitro and in vivo models demonstrate that Sost/Sclerostin expression is elevated in 
osteocytes. Further, Sost/Sclerostin upregulation in osteocytes was associated with decreased 
Wnt signaling in osteoblasts and reduced osteoblast differentiation. In addition, the 
expression of Wnt target genes, including OPG, was reduced; thereby further increasing the 
Rankl/Opg ratio. These results suggest that osteocytes contribute to the generation of a MM 
microenvironment with high Sclerostin concentrations, affecting both bone formation and 
bone resorption.
Physical interactions between MM cells and different cells in the bone microenvironment, 
including stromal cells, osteoclasts and immune cells, were shown to be important for tumor 
proliferation and survival (49). Our results suggest that osteocytes also contribute to MM 
cell growth and MM induced bone disease by stimulating osteoclast recruitment and 
inhibiting bone formation via direct and indirect contact with MM cells. Since osteocytes 
comprise more than 95% of the bone cells, they should be major contributors to generating a 
microenvironment favorable for MM progression. However, the relative contribution of 
osteocytes versus other cell types in the bone/BM microenvironment to MM disease remains 
to be determined.
Our study identified pathways activated by interactions between MM cells and osteocytes 
that provide potential new ways to inhibit MM tumor growth and bone disease. Prevention 
of osteocyte apoptosis might suppress initiation of bone resorption by inhibiting osteoclast 
recruitment as well as improving the bone fragility syndrome associated with MM and with 
some of the current anti-tumor drugs (eg. glucocorticoids that also increase osteocyte 
apoptosis). Pharmacological inhibition of Notch signaling can inhibit MM cell growth (50, 
51) and could provide additional benefits by inhibiting osteocyte apoptosis, either alone or 
in combination with TNFα signaling blockade. Our findings demonstrate that osteocytes 
regulate the expression and repertoire of Notch receptors on MM cells, supporting 
development of therapeutic approaches that block specific Notch receptors. This approach 
might be an effective alternative to overcome the side-effects associated with generalized 
Notch inhibition (36).
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Figure 1. Osteocytes interact with MM tumors in the BM to increase apoptosis, RANKL and 
Sclerostin production in osteocytes in a murine model of human MM
(A) Osteolytic lesions were detected by radiographs, micro-CT and histology 4wks after 
injection. Representative images of tibiae are shown. (B) micro-CT analysis of cancellous 
bone in tumor-bearing tibias (n=5/group). (C) Percentage of cortical osteocytes stained for 
active CASP3, RANKL, or Sclerostin (n=5–7/group). *p<0.05 vs saline. (D) MM cells 
adjacent to osteocytes in bone detected by H&E. Black arrows point to osteocytes and the 
yellow arrow points to an osteoclasts on the bone surface. (E) Osteocytes in direct contact 
with MM tumors detected by acid etching-SEM. Areas indicated by boxes a and b are 
magnified on the right. Arrows point to osteocytic cytoplasmic projections in contact with 
the bone marrow (BM) compartment.
Delgado-Calle et al. Page 15
Cancer Res. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. MM-induced osteocyte apoptosis is triggered by activation of Notch signaling in 
osteocytes and sustained by MM-derived TNFα
(A) Cell death, measured by trypan blue uptake and apoptosis (24h), measured by nuclear 
morphology, were quantified in MLO-A5 cells co-cultured in direct contact with JJN3 MM 
cells or CD138+ cells isolated from 6 MM patients, with or without the caspase inhibitor 
DEVD for 24h. (B) MLO-A5 cell death or apoptosis (24h) was quantified in co-cultures in 
indirect contact with JJN3 cells, cultured with 48h conditioned medium (CM) collected from 
JJN3 cultured alone, or 48h-CM from primary CD138+ cells from a MM patient with or 
without the caspase inhibitor DEVD. Representative experiments out of 3 (n=3–8) are 
shown (C and D) Hey1, Notch1, 2, 3 and 4 expression in MLO-A5 cells co-cultured for 4h 
in direct contact with JJN3 MM cells or CD138+ cells from MM patients. Data from one 
well per condition are reported for patient #1; 3 wells per condition are reported for the other 
patients (E) Percentage of cortical osteocytes stained for NOTCH3 (n=3–7/group). *p<0.05 
vs saline. (F) Protein levels of NICD3, the activated form of the NOTCH3 receptor, in bone 
lysates obtained from saline- and JJN3-injected tibias.
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Figure 3. Activation of Notch signaling induces osteocyte apoptosis
(A) Apoptosis was measured by nuclear morphology in MLO-A5 cells co-transfected with 
nGFP and vectors overexpressing NICD1 or NICD2 and quantified after 24h. (B) Cell death 
measured by trypan blue uptake and Hes1 expression (qPCR) were quantified in MLO-A5 
after 24h culture on DLL1-coated plates with or without GSIXX or DEVD. (C) Cell death 
of MLO-A5 cells co-cultured in direct contact with JJN3 cells or CD138+ from a MM 
patient with or without the Notch inhibitor GSIXX or the caspase inhibitor DEVD. (D) 
TNFα protein levels secreted to the media by JJN3 MM cells. MLO-A5 cell death quantified 
in co-cultures in indirect contact with JJN3 cells, with or without DEVD, anti-TNFα 
(aTNFα) or GSIXX, as indicated. (E) Cell death of MLO-A5 quantified in co-cultures in 
direct contact with JJN3 cells, with or without DEVD, GSIXX, anti-TNFα or a combination 
of GSIXX and anti-TNFα. Representative experiments out of 3 (n=3–8) are shown. *p<0.05 
vs MLO-A5 cultured alone (veh), vs vector-transfected cells (A), or vs cells plated on IgG2-
coated plates (B).
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Figure 4. Osteocyte apoptosis induced by MM increases the osteoclastogenic potential of 
osteocytes
(A, B) Rankl gene expression in MLO-A5 cells co-cultured in direct or indirect contact with 
JJN3 cells (4h) or primary CD138+ cells from MM patients (24h), with or without anti-
TNFα or DEVD (24h). (C) Osteoclast precursor migration induced by conditioned media 
(CM) collected from JJN3 cells cultured alone, MLO-A5 cultured alone or MLO-A5 co-
cultured with JJN3 cells in direct contact for 48h, with or without DEVD or a combination 
of GSIXX and anti-TNFα (aTNFα). Representative experiments out of 2 (n=3–4) are 
shown. *p<0.05 vs MLO-A5 cells cultured alone (veh), vs osteoclast precursors cultured in 
the presence of CM from MLO-A5 cells cultured alone (C).
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Figure 5. MM increases Sost expression in osteocytes, which decreases Wnt signaling and 
osteoblasts differentiation
(A) Sost, Opg, and Wnt target genes mRNA levels in MLO-A5 cells co-cultured in direct or 
indirect contact with JJN3 cells (4h). (B) Sost expression in authentic osteocytes co-cultured 
with 5TGM1 MM cells in ex vivo bone organ cultures (48h). (C) Osteoblast marker 
expression (Alp, Col1a, Runx2 and Bglap) and Wnt target genes (Axin2 and Smad6) in 
osteoblasts cultured in osteogenic media with or without 50% CM from JJN3 cells cultured 
alone, MLO-A5 cultured alone or MLO-A5 co-cultured with JJN3 cells in direct contact for 
48h. Representative experiments out of 2 (n=3–6) are shown. *p<0.05 vs MLO-A5 cells 
cultured alone (A), vs authentic osteocytes (bone) (B), vs osteoblast cultured with 
osteogenic media (OM) and without CM (C).
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Figure 6. Osteocytes activate Notch signaling, regulate Notch receptor expression, and increase 
proliferation in MM cells
(A, B) Hes1 and Hey1 gene expression in 5TGM1 MM cells or CD138+ cells from 3 
different MM patients co-cultured in direct contact with MLO-A5 cells, with or without 
GSIXX. Data from one well per condition are reported for patient #1; 3 wells per condition 
are reported for the other patients. (C) Cell growth of 5TGM1 cells measured as RFU 
(relative fluorescence units), cultured alone or co-cultured in direct contact with MLO-A5 
cells, with or without GSIXX. (D) Time course of Notch receptors expression in 5TGM1 
cells co-cultured with MLO-A5 cells for 4, 24, 48 and 72h. For Notch1, 2 and 3 expression, 
fold changes were calculated vs 5TGM1 cells cultured alone. For Notch4 expression, fold 
change was calculated vs Notch4 expression in 5TGM1 cells co-cultured with MLO-A5 for 
4h. Cell proliferation (number of viable cells), Hey1 and Notch1, 2, 3 and 4 gene expression 
in CD138+ cells from a MM patient in which MLO-A5 cells induce (E) or not (F) Notch 
activation. (G) Hey1 and Notch1, 2, 3 and 4 gene expression in 5TGM1 cells co-cultured 
with authentic osteocytes in ex vivo bone organ cultures. A representative experiment of 2 
(n=4) is shown. *p<0.05 vs MM cells cultured alone (veh), vs MM cultured with MLO-A5 
for 4h (D, Notch4).
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Figure 7. Interactions between MM cells and osteocytes generate a microenvironment conducive 
to increased tumor growth and bone destruction
Cell-to-cell contact activates bidirectional Notch signaling in osteocytes and MM cells and 
triggers osteocyte apoptosis that is maintained by MM-secreted TNFα. Apoptosis enhances 
the osteoclastogenic potential of osteocytes by increasing osteoclast precursor recruitment 
and osteocytic RANKL expression. Notch signaling in MM cells increases proliferation, and 
upregulates Notch1, 2 and 3, in patient MM cells. MM cells increase Sost/Sclerostin 
expression in osteocytes, which decreases Wnt signaling and inhibits osteoblast 
differentiation.
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